MA50433A - Protéines à greffe de cytokine-anticorps et procédés d'utilisation contre des troubles liés à l'immunité - Google Patents

Protéines à greffe de cytokine-anticorps et procédés d'utilisation contre des troubles liés à l'immunité

Info

Publication number
MA50433A
MA50433A MA050433A MA50433A MA50433A MA 50433 A MA50433 A MA 50433A MA 050433 A MA050433 A MA 050433A MA 50433 A MA50433 A MA 50433A MA 50433 A MA50433 A MA 50433A
Authority
MA
Morocco
Prior art keywords
cytokine
antibody
methods
related disorders
use against
Prior art date
Application number
MA050433A
Other languages
English (en)
Inventor
Yaiza Diaz-De-Durana
Michael Didonato
Christophe Filippi
Shelly Meeusen
Glen Spraggon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA50433A publication Critical patent/MA50433A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/197—Treatment of whole grains not provided for in groups A23L7/117 - A23L7/196
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02B—PREPARING GRAIN FOR MILLING; REFINING GRANULAR FRUIT TO COMMERCIAL PRODUCTS BY WORKING THE SURFACE
    • B02B1/00—Preparing grain for milling or like processes
    • B02B1/04—Wet treatment, e.g. washing, wetting, softening
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C23/00—Auxiliary methods or auxiliary devices or accessories specially adapted for crushing or disintegrating not provided for in preceding groups or not specially adapted to apparatus covered by a single preceding group
    • B02C23/18—Adding fluid, other than for crushing or disintegrating by fluid energy
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C23/00—Auxiliary methods or auxiliary devices or accessories specially adapted for crushing or disintegrating not provided for in preceding groups or not specially adapted to apparatus covered by a single preceding group
    • B02C23/18—Adding fluid, other than for crushing or disintegrating by fluid energy
    • B02C23/40—Adding fluid, other than for crushing or disintegrating by fluid energy with more than one means for adding fluid to the material being crushed or disintegrated
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C4/00—Crushing or disintegrating by roller mills
    • B02C4/02—Crushing or disintegrating by roller mills with two or more rollers
    • B02C4/06—Crushing or disintegrating by roller mills with two or more rollers specially adapted for milling grain
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C4/00—Crushing or disintegrating by roller mills
    • B02C4/10—Crushing or disintegrating by roller mills with a roller co-operating with a stationary member
    • B02C4/12—Crushing or disintegrating by roller mills with a roller co-operating with a stationary member in the form of a plate
    • B02C4/16—Crushing or disintegrating by roller mills with a roller co-operating with a stationary member in the form of a plate specially adapted for milling grain
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C9/00—Other milling methods or mills specially adapted for grain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C15/00—Disintegrating by milling members in the form of rollers or balls co-operating with rings or discs
    • B02C15/14—Edge runners, e.g. Chile mills
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
MA050433A 2017-05-24 2018-05-22 Protéines à greffe de cytokine-anticorps et procédés d'utilisation contre des troubles liés à l'immunité MA50433A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762510514P 2017-05-24 2017-05-24

Publications (1)

Publication Number Publication Date
MA50433A true MA50433A (fr) 2020-09-02

Family

ID=62685010

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050433A MA50433A (fr) 2017-05-24 2018-05-22 Protéines à greffe de cytokine-anticorps et procédés d'utilisation contre des troubles liés à l'immunité

Country Status (25)

Country Link
US (3) US11122825B2 (fr)
EP (1) EP3630812A1 (fr)
JP (2) JP7093794B2 (fr)
KR (1) KR102381237B1 (fr)
CN (1) CN110650973B (fr)
AR (1) AR112239A1 (fr)
AU (2) AU2018274215B2 (fr)
BR (1) BR112019024544A2 (fr)
CA (1) CA3063527A1 (fr)
CL (1) CL2019003392A1 (fr)
CO (1) CO2019013000A2 (fr)
CR (1) CR20190535A (fr)
CU (1) CU20190093A7 (fr)
EA (1) EA201992776A1 (fr)
EC (1) ECSP19083343A (fr)
IL (1) IL270772B2 (fr)
JO (1) JOP20190271A1 (fr)
MA (1) MA50433A (fr)
MY (1) MY200872A (fr)
PE (1) PE20200302A1 (fr)
PH (1) PH12019502617A1 (fr)
TW (1) TWI825020B (fr)
UY (1) UY37738A (fr)
WO (1) WO2018215935A1 (fr)
ZA (1) ZA201907481B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056630A1 (fr) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Immunotolerance ciblee
CA3064435A1 (fr) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Immunotolerance ciblee
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (fr) 1989-10-25 1991-05-16 The University Of Melbourne MOLECULES RECEPTRICES Fc HYBRIDES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1993022332A2 (fr) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes
EP0714409A1 (fr) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Anticorps
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
CA2196200A1 (fr) 1994-07-29 1996-02-15 Michael Joseph Browne Nouveaux composes
CA2205572A1 (fr) 1994-12-12 1996-06-20 Beth Israel Hospital Association Cytokines chimeres et emplois de celles-ci
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
WO1997034631A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1724282B1 (fr) 1997-05-21 2013-05-15 Merck Patent GmbH Procédé de production de protéines non-immunogènes
BR9908226A (pt) 1998-02-25 2000-10-24 Lexigen Pharm Corp Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US7279462B1 (en) 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
ATE501175T1 (de) * 1999-04-27 2011-03-15 Nevagen Llc Somatische transgene immunisierung und darauf bezogene verfahren
AU2002223350A1 (en) 2000-12-01 2002-06-11 Eleanor N. Fish Cytokine receptor binding peptides
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
EP1642910B1 (fr) 2000-12-05 2012-02-08 Alexion Pharmaceuticals, Inc. Anticorps conçus de manière rationnelle
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
EP1443961B1 (fr) 2001-10-25 2009-05-06 Genentech, Inc. Compositions de glycoproteine
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US8603472B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
EP1572937B1 (fr) 2002-04-09 2012-02-08 The Scripps Research Institute Polypeptides hybrides a greffe de motif structural et utilisations de ceux-ci
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004072266A2 (fr) 2003-02-13 2004-08-26 Kalobios Inc. Ingenierie de l'affinite des anticorps par un remplacement complementaire en serie guide par epitope
WO2004108078A2 (fr) 2003-06-02 2004-12-16 Alexion Pharmaceuticals Inc. Anticorps conçus de maniere rationnelle
CA2553692C (fr) 2004-01-20 2014-10-07 Kalobios, Inc. Transfert de specificite d'anticorps au moyen de determinants de liaison essentielle minimale
AU2005302453A1 (en) 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
WO2006055778A2 (fr) 2004-11-16 2006-05-26 Kalobios, Inc. Echange de cassettes d'une region variable de l'immunoglobuline
GB0502358D0 (en) 2005-02-04 2005-03-16 Novartis Ag Organic compounds
SG10201605629VA (en) 2008-01-03 2016-08-30 Scripps Research Inst Antibody targeting through a modular recognition domain
NZ603712A (en) 2009-02-24 2014-05-30 Alexion Pharma Inc Antibodies containing therapeutic tpo/epo mimetic peptides
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
WO2012045334A1 (fr) 2010-10-05 2012-04-12 Synthon Bv Protéines de fusion de l'il‑10 biologiquement actives
DK3489255T3 (da) 2011-02-10 2021-08-23 Roche Glycart Ag Muterede interleukin-2-polypeptider
CN103476433A (zh) 2011-02-10 2013-12-25 罗切格利卡特公司 改良的免疫疗法
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
AU2013208003B2 (en) * 2012-01-09 2017-12-14 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
CN104411717A (zh) 2012-01-09 2015-03-11 斯克利普斯研究所 具有超长cdr3s的人源化抗体
MX365382B (es) 2012-08-07 2019-05-31 Roche Glycart Ag Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
WO2014023673A1 (fr) 2012-08-08 2014-02-13 Roche Glycart Ag Protéines de fusion de l'interleukine-10 et leurs utilisations
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CN105073781A (zh) 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
AU2014225307A1 (en) 2013-03-08 2015-09-24 The Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
WO2015006736A2 (fr) 2013-07-11 2015-01-15 The California Institute For Biomedical Research Protéines de fusion d'immunoglobulines en hélice superenroulée et compositions à base de celles-ci
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
EP3022221B1 (fr) 2013-07-18 2021-09-15 Taurus Biosciences, LLC Anticorps humanisés comprenant des régions déterminant la complémentarité ultralongues
MA39250B1 (fr) * 2014-02-06 2018-09-28 Hoffmann La Roche Protéines hybrides de l'interleukine-2 et leurs utilisations
SI3186283T1 (sl) 2014-08-29 2020-04-30 F. Hoffmann-La Roche Ag Kombinirana terapija z imunocitokini različice IL-2, usmerjenimi proti tumorju in protitelesi proti humanemu PD-L1
SG11201804259UA (en) * 2015-12-04 2018-06-28 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
EA201992776A1 (ru) 2020-10-12
CA3063527A1 (fr) 2018-11-29
CO2019013000A2 (es) 2020-01-17
AR112239A1 (es) 2019-10-09
PH12019502617A1 (en) 2020-06-08
CN110650973B (zh) 2023-02-24
IL270772B1 (en) 2023-04-01
RU2019142660A3 (fr) 2021-10-05
IL270772A (en) 2020-01-30
CU20190093A7 (es) 2021-03-11
CL2019003392A1 (es) 2020-03-13
UY37738A (es) 2019-01-02
CR20190535A (es) 2020-01-15
TWI825020B (zh) 2023-12-11
KR20200008614A (ko) 2020-01-28
KR102381237B1 (ko) 2022-04-01
MY200872A (en) 2024-01-20
JP2020520667A (ja) 2020-07-16
WO2018215935A1 (fr) 2018-11-29
JOP20190271A1 (ar) 2019-11-21
CN110650973A (zh) 2020-01-03
US20200113974A1 (en) 2020-04-16
AU2018274215B2 (en) 2021-10-28
EP3630812A1 (fr) 2020-04-08
JP2022130504A (ja) 2022-09-06
US20220039441A1 (en) 2022-02-10
PE20200302A1 (es) 2020-02-06
AU2018274215A1 (en) 2019-12-12
JP7093794B2 (ja) 2022-06-30
RU2019142660A (ru) 2021-06-24
US20220346415A1 (en) 2022-11-03
US11122825B2 (en) 2021-09-21
ECSP19083343A (es) 2019-11-30
IL270772B2 (en) 2023-08-01
ZA201907481B (en) 2023-02-22
US11930837B2 (en) 2024-03-19
AU2022200528A1 (en) 2022-02-17
BR112019024544A2 (pt) 2020-06-23
TW201900222A (zh) 2019-01-01

Similar Documents

Publication Publication Date Title
MA50433A (fr) Protéines à greffe de cytokine-anticorps et procédés d'utilisation contre des troubles liés à l'immunité
MA52781A (fr) Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA46290A (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA50077A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA48772A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA44507A (fr) Récepteurs chimères de flt3 et leurs procédés d'utilisation
MA41463A (fr) Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA44993A (fr) Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
MA55472A (fr) Molécules de liaison de lymphopoïétine stromale thymique (tslp) et procédés d'utilisation des molécules
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
MA54851A (fr) Oxystérols et leurs procédés d'utilisation
MA53235A (fr) Indoles substitués et procédés d'utilisation associés
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA42409A (fr) Oxystérols et leurs procédés d'utilisation